Integral Health Asset Management LLC Takes $8.55 Million Position in IQVIA Holdings Inc. $IQV

Key Points

• Integral Health Asset Management bought a new stake of 45,000 shares in IQVIA during Q3, valued at about $8.55 million.
• IQVIA slightly beat quarterly estimates with $3.42 EPS vs. $3.40 expected and $4.36B revenue (up 10.3% YoY), and set FY2026 guidance of 12.55–12.85 EPS.
• Analysts are largely positive — the consensus rating is "Buy" with an average target of $229.13 despite several target cuts — and institutional investors own about 89.62% of the stock.

Integral Health Asset Management LLC purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 45,000 shares of the medical research company's stock, valued at approximately $8,547,000.

A number of other hedge funds also recently bought and sold shares of the business. Physician Wealth Advisors Inc. raised its stake in shares of IQVIA by 1,340.0% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company's stock worth $27,000 after buying an additional 134 shares during the period. Westside Investment Management Inc. grew its stake in IQVIA by 219.6% in the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company's stock valued at $30,000 after acquiring an additional 101 shares during the period. Atlantic Union Bankshares Corp purchased a new stake in IQVIA in the 3rd quarter worth $36,000. Root Financial Partners LLC acquired a new position in IQVIA during the third quarter worth $43,000. Finally, Hantz Financial Services Inc. lifted its holdings in IQVIA by 92.0% during the third quarter. Hantz Financial Services Inc. now owns 240 shares of the medical research company's stock valued at $46,000 after purchasing an additional 115 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company's stock.

IQVIA Stock Up 1.1%

Shares of NYSE IQV opened at $164.78 on Friday. The stock has a market cap of $27.96 billion, a PE ratio of 20.96, a P/E/G ratio of 1.57 and a beta of 1.39. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.09. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $247.04. The company has a 50-day moving average of $201.58 and a 200 day moving average of $206.67.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, topping analysts' consensus estimates of $3.40 by $0.02. The business had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The business's revenue was up 10.3% on a year-over-year basis. During the same period last year, the company posted $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. JPMorgan Chase & Co. cut their target price on shares of IQVIA from $255.00 to $225.00 and set an "overweight" rating for the company in a research note on Friday, February 6th. Wall Street Zen upgraded IQVIA from a "hold" rating to a "buy" rating in a report on Saturday, February 21st. Jefferies Financial Group cut their price objective on IQVIA from $270.00 to $255.00 and set a "buy" rating for the company in a research note on Friday, February 6th. Mizuho set a $215.00 target price on IQVIA in a research report on Monday, February 23rd. Finally, BMO Capital Markets set a $250.00 price target on IQVIA in a research note on Friday, February 6th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $229.13.

IQVIA Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.